Rilematovir

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameRilematovir
Drug Alias NameJNJ-678JNJ-53718678JNJ-5371678JNJ-8678
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionViral fusion proteins inhibitors
TargetsViral fusion proteins
Therapy Area/IndicationsHepatic InsufficiencyRespiratory Syncytial Virus InfectionsVirus Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJanssen Sciences Ireland Uc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Pharmaceutica NVJanssen Research & Development Llc
Inactive CompaniesJanssen Sciences Ireland Unlimited CompanyJanssen Sciences Ireland Uc
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsHepatic InsufficiencyVirus DiseasesRespiratory Tract Infections

Other Information

ATC CodeN/A
Related LinksDrugBank